Loading...
Market
Vaccination Rates in Top Adopting Countries by 2025
3
Resolution / Starting Odds
Over 50% vaccination rate • 25%
30-50% vaccination rate • 25%
10-30% vaccination rate • 25%
Under 10% vaccination rate • 25%
National health department reports or WHO vaccination data
Story
WHO Prequalifies Takeda's New Second Dengue Vaccine Amid Rising Outbreaks
May 15, 2024, 05:16 PM
The World Health Organization (WHO) has prequalified Takeda Pharmaceuticals' new dengue vaccine, marking it as the second dengue vaccine approved amid rising outbreaks in the Americas. The WHO recommends the vaccine for use in children aged 6 to 16 years in areas with high dengue burden and transmission intensity. This new vaccine aims to boost the fight against dengue fever, a vector-borne disease transmitted by mosquitoes, with over 100-400 million cases reported worldwide each year.
View original story
Similar markets
Less than 10 • 33%
10 to 20 • 33%
More than 20 • 33%
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Over 60% • 25%
Below 50% effective • 33%
50% to 75% effective • 34%
Above 75% effective • 33%
0-5% • 25%
6-10% • 25%
11-15% • 25%
Over 15% • 25%
Adopted in 1-5 countries • 25%
Adopted in 6-10 countries • 25%
Adopted in 11-20 countries • 25%
Adopted in 21 or more countries • 25%
Below 50% effective • 25%
50-69% effective • 25%
70-89% effective • 25%
90% or more effective • 25%
Recommendation against vaccines for under 50s • 25%
No change in current recommendation • 25%
Stronger endorsement of vaccines for under 50s • 25%
Recommendation under review • 25%
Under 50% effective • 33%
50-75% effective • 33%
Over 75% effective • 33%
Below 20% effective • 25%
20-40% effective • 25%
41-60% effective • 25%
Above 60% effective • 25%
Less than 20 countries • 33%
20-50 countries • 34%
More than 50 countries • 33%
Below 50% effective • 25%
50%-70% effective • 25%
71%-90% effective • 25%
More than 90% effective • 25%
Below 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
Above 75% • 25%